Brief: Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million
27/02/2026 01:41
Feb 27 (Reuters) - Mesoblast Ltd MSB.AX: SEES FULL-YEAR FISCAL 2026 RYONCIL NET REVENUE TO RANGE BETWEEN US$110 MILLION AND US$120 MILLION Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M